Compare KGC & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KGC | RMD |
|---|---|---|
| Founded | 1993 | 1989 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9B | 36.4B |
| IPO Year | N/A | 1995 |
| Metric | KGC | RMD |
|---|---|---|
| Price | $30.75 | $250.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $28.80 | ★ $289.09 |
| AVG Volume (30 Days) | ★ 7.5M | 916.6K |
| Earning Date | 02-11-2026 | 01-29-2026 |
| Dividend Yield | 0.40% | ★ 0.96% |
| EPS Growth | ★ 137.72 | 29.59 |
| EPS | 1.43 | ★ 9.77 |
| Revenue | ★ $6,443,900,000.00 | $5,257,400,000.00 |
| Revenue This Year | $38.79 | $9.85 |
| Revenue Next Year | $16.72 | $7.36 |
| P/E Ratio | ★ $21.62 | $25.68 |
| Revenue Growth | ★ 32.90 | 9.36 |
| 52 Week Low | $9.83 | $199.92 |
| 52 Week High | $30.94 | $293.81 |
| Indicator | KGC | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 55.23 |
| Support Level | $28.93 | $240.00 |
| Resistance Level | $28.98 | $250.15 |
| Average True Range (ATR) | 0.98 | 4.08 |
| MACD | 0.10 | 0.89 |
| Stochastic Oscillator | 99.12 | 90.87 |
Kinross Gold is a Canada-based gold producer, producing roughly 2.1 million gold equivalent ounces in 2024. The company had about a decade of gold reserves at the end of 2024. It operates mines in the Americas and West Africa after selling its low-cost Russian operations in 2022 in response to the invasion of Ukraine. Kinross has historically used acquisitions to fuel expansion into new regions and production growth. In 2022, Kinross purchased the Great Bear project in Canada. If developed as we think likely, it could produce an average of more than 500,000 ounces of gold per year for at least a decade, with its unit cash costs likely in the first quartile of the industry cost curve. Though Great Bear's production is likely to be replacement ounces for falling volumes at other mines.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.